Loading…

OmniAb, Inc.OABICompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services
Momentum leader 96
Mkt cap
$741M
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$7.22M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-26.0 pp
WACC 8.0%
Hurdle
+92 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · USD$5.08
1D+0.6%
1W-0.4%
1M+2.4%
3M+18.1%
6M+96.9%
YTD+174.6%
1Y+234.2%
ATR %6.3%
Beta1.21
52w lowhigh6.8% off high

What OmniAb does

Employees: 89

OmniAb at a glance

Size OmniAb (OABI) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $741M, the 2424th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.08 on 18 Nov 2026.

Performance Over six months the shares gained 96.9%, against +1.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 10 in its peer set.

Growth Revenue grew 90.6% over the last twelve months (peer median +1.1%); the operating margin is -115.5% (peer median -1.3%).

Valuation It trades at 17.3× enterprise value to sales against a peer median of 1.9× (3rd most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 61% a year for seven years (Req g). Recent delivered growth is -32%, so the hurdle is +92 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 26.0 points below its cost of capital (8.0% WACC).

Short interest Short interest is 5.5% of the free float (30 Oct 2026).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026OABI 199Peer median 102
Six months, rebased to 100: OmniAb against the median of its 9 peers (local-currency closes).

OmniAb financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$40.2M$18.7M$26.4M$34.2M$59.1M
Revenue growth—-29%-23%-42%—
Gross profit$15.9M-$3.39M$6.71M$14.7M$42.8M
EBITDA-$23.1M-$49.8M-$53.3M-$49.7M-$11.0M
Net income-$43.5M-$64.8M-$62.0M-$50.6M-$22.3M
Free cash flow$2.38M-$37.0M-$41.5M$703,000-$20.8M
Capital expenditure$286,000$565,000$1.88M$1.64M$17.2M
Total debt$18.1M$20.3M$23.2M$25.6M$25.8M

Quarterly statements and history in the cockpit →

OmniAb competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%SBCANLEVTOCSSLNEVHTECXFTREPGNYOABI6-month return →1-month return →
Up and to the right = strong over both horizons. OmniAb is the large dot.

Fundamentals: revenue growth against valuation

-100%-50%0%+50%+100%0×1,000×2,000×SBCEVTSLNOABIRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OmniAb is the large dot.

Capital: growth delivered against growth the price implies

-25%0%+25%+50%0%50%SBCEVHFTREPGNYOABIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. OmniAb is the large dot.

OmniAb competitors and peer comparison

How OmniAb compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OmniAb against its 9 peers (data as of 18 Nov 2026)
MeasureOABIPeer medianRank in peer set
1-month return+2.4%-1.3%3rd highest of 10
6-month return+96.9%+1.8%2nd highest of 10
Distance from 52-week high-6.8%-37.2%3rd highest of 10
Revenue growth (TTM)+90.6%+1.1%highest of 7
Operating margin-115.5%-1.3%3rd lowest of 8
EV / Sales17.3×1.9×3rd most expensive of 8
Growth the price implies (Req g, 7 yrs)60.6%11.3%most demanding of 5
Growth delivered (Del g)-31.9%+10.9%lowest of 5
Hurdle (Req g minus delivered)+92.4 pp-11.4 ppmost demanding of 5
ROIC minus cost of capital-26.0 pp-8.7 pplowest of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
OmniAb OABIUnited States$741M+97%+91%-116%17.3×60.6%-31.9%
SBC Medical SBCUnited States$645M+94%+7%40%2.6×-15.7%+6.7%
Adlai Nortye Ltd. Sponsored ADR ANLUnited States$610M-23%n/a-134%22.3×n/an/a
Evotec EVT.DEGermany$532M-46%-5%-15%0.8×n/an/a
Oculis OCSUnited States$456M-74%n/an/an/an/an/a
Silence Therapeutics PLC Sponsored ADR SLNUnited States$1.23B+244%-98%-11,920%2,161.6×n/an/a
Evolent Health EVHUnited States$445M+2%+14%-1%0.5×14.0%+15.2%
Tectonic Therapeutic TECXUnited States$420M-27%n/an/an/an/an/a
Fortrea FTREUnited States$1.98B+50%-3%2%1.1×31.9%+1.1%
Progyny PGNYUnited States$2.66B+41%+6%9%1.9×8.6%+30.2%

Questions

Which companies are OmniAb's closest peers?
The cockpit's peer set: SBC Medical (SBC), Adlai Nortye Ltd. Sponsored ADR (ANL), Evotec (EVT.DE), Oculis (OCS), Silence Therapeutics PLC Sponsored ADR (SLN), Evolent Health (EVH), Tectonic Therapeutic (TECX), Fortrea (FTRE).
Is OmniAb expensive compared with its peers?
On ev / sales it trades at 17.3× against a peer median of 1.9×, 3rd most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 61% a year for seven years (Req g). Recent delivered growth is -32%, so the hurdle is +92 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has OmniAb stock performed?
Over six months to 18 Nov 2026 the shares returned +96.9% against +1.8% for the median peer; over one year +234.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.